Sulforaphane as an adjunctive treatment for irritability in children with autism spectrum disorder: A randomized, double-blind, placebo-controlled clinical trial.

Sara MomtazmaneshZeinab Amirimoghaddam-YazdiHossein Sanjari MoghaddamMohammad Reza Mohammadi Shahin Akhondzadeh

Published in: Psychiatry and clinical neurosciences (2020)

Our results support the safety and efficacy of sulforaphane as an adjuvant to risperidone for improvement of irritability and hyperactivity symptoms in children with ASD.

Keyphrases

double blind
placebo controlled
clinical trial
phase ii
phase iii
study protocol
autism spectrum disorder
early stage
young adults
attention deficit hyperactivity disorder
open label
intellectual disability
depressive symptoms